ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 31 of 43
JMBS 2017, 2(2): 185–192
Medicine. Reviews

Morphofunctional Features of Apoptosis, Issues and Perspectives of Apoptosis Usage in Modern Medicine

Khlamanova L. I., Severylova M. D., Tkachenko Yu. V.

Apoptosis (programmed cell death) is a chain of complex biochemical processes that regulate the cellular mechanisms. The study of apoptosis is a rapidly developing field, but its role is still not precise and controversial. This review discusses issues of apoptosis in the context of normal aging T-cells, cardiac myocytes, and cells of neural tissue. A special attention is given to caspases, death receptors, mitochondria, Bcl-2, Bcl-x and tumor suppressor genes, since they are considered to be the most important mediators of the programmed cell death. This review presents data of modern literature on the mechanisms of apoptosis, its difference from necrosis, the molecular and genetic bases of its activation. Apoptosis is regulated by proteolytic enzymes called caspases, which activate cell death process by cleaving specific proteins. The activation is initiated either by extracellular or intracellular death signals, which is why there are two pathaways of initiation: an extrinsic and an intrinsic one. An article focuses on the essential role of apoptosis in morphogenesis, embryogenesis and tissue growth, its importance in biology and medicine, and in the maintenance of homeostasis. Apoptosis is overviewed at the molecular and cellular levels, special attention is paid to the proteins and inhibitors of this process, as well as to its biomarkers. Apoptosis involves a cascade of complicated processes that include the delivery of signals through the receptor complexes, an execution of programmed cell death by proteases and endonucleases and the well-regulated expression of a number of genes. The latest studies are aimed at the connection of apoptosis and various pathological conditions. More frequently diseases are caused either by extensive, or by insufficient apoptosis. But the pathologies may also occur due to defects or abnormalities of the process itself. The attention is also given to the role of apoptosis in the theory of schizophrenia and the theory of aging. It was proved, that anomalies in the regulation of the apoptosis are crucial to the development of diseases such as cancer, AIDS, myocardial infarction and stroke, ischemia and neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease and amyotrophic lateral sclerosis. With a better understanding of the molecular mechanisms, that regulate the death pathaway and further investigation in problems of the programmed cell death, it is clear, that an enormous amount of opportunities will become opened. The scientists will be able to devise targeted therapies and new treatment strategies. However, before the use of new ways of treatment and drugs, before they can be used safely on humans, a multiple amount of critical tests must be passed. But surely apoptosis will be further studied and can become a key to not only understanding the worst diseases, but also to their treatment.

Keywords: apoptosis, theory of apoptosis, mechanism of apoptosis regulation, induction of apoptosis, importance of apoptosis in medicine, programmed cell death, perspectives of apoptosis

Full text: PDF (Ukr) 1.34M

  1. Apoptoz - zaprogrammirovannaya gibel' kletki. Available from::
  2. Baryshnikov AYu Shishkin YuV. Immunologicheskiye problemy apoptoza. Yeditorial URSS; 2002. 320 s.
  3. Burtsev EM, Grinshteyn VB. Primeneniye T-aktivina v lechenii ishemicheskogo insul'ta. Klinicheskaya nevropatologiya i neyrokhirurgiya v Vyatskom kraye: Tr. nauch-prakt konf nevropat, neyrokhirurg, det nevropatolog, psikhiatr, posvyashch. 10-let kaf nevrolog, neyrokhirurg i med genetiki. Kirov; 1999: 30-2.
  4. Velikiy NN. Otchet ob opredelenii kolichestvennogo i kachestvennogo sostava preparata GA-40. K.: Institut biokhimii im Palladina NAN Ukraine, 2007.
  5. Vikipediya — svobodnaya entsiklopediya. Available from:
  6. Vladimirskaya EB. Apoptoz i yego rol' v regulyatsii kletochnogo ravnovesiya. Klin lab diagnostika. 2002; 11: 25-32.
  7. Gordeyeva AV, Labas YuA, Zvyagil'skaya RA. Apoptoz odnokletochnykh organizmov: mekhanizmy i evolyutsiya. Biokhimiya. 2004; 69 (10): 1301-13.
  8. Kukhta VK, Morozkina NV, Bogatyreva EV, Sokol'chik IG. Molekulyarnyye mekhanizmy apoptoza. Meditsinskiy zhurnal. 2004; 1: 30-3.
  9. Likhtenshteyn AV, Shapot VS. Opukholevyy rost: tkani, kletki, molekuly. Patol fiziol. 1997; 3: 35-48.
  10. Lopukhin YuM, Martynov AK. Issledovaniye kletochnykh i molekulyarnykh mekhanizmov deystviya preparata GA-40. M: GU NII FKHM, 2006. Available from:
  11. Manskikh VN. Morfologicheskiye metody verifikatsii i kolichestvennoy otsenki apoptoza. Byulleten' sibirskoy meditsiny. 2004; 1: 63-70.
  12. Murashko NK. Pozitivní y negativní naslídki apoptozu v medichníy praktitsí. Líkaryu-praktiku. 2008; 4 (10). Available from:
  13. Yarilin AA. Apoptoz i yego mesto v immunnykh protsessakh. Immunologiya. 1996; 6: 10-23.
  14. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006; 95: 998-1004.
  15. Goodin S. Erlotinib: optimizing therapy with predictors of response? Clin Cancer Res. 2006; 12: 2961-3.
  16. Imyanitov EN, Kuligina ESh, Belogubova EV, Togo AV, Hanson KP. Mechanisms of lung cancer. Drug Discov Today: Dis Mech. 2005a; 2: 213-23.
  17. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T, Oh-Hara T, Tsuruo T. Predominant Suppression of Apoptosome by Inhibitor of Apoptosis Protein in Non-Small Cell Lung Cancer H460 Cells: Therapeutic Effect of a NovelPolyarginine-conjugated Smac Peptide. Cancer Res. 2003 Feb 15; 63 (4): 831-7.
  18. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26 (4): 239-57.
  19. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005; 65: 7096-101.
  20. Kroemer G, Galluzzi L, P Vandenabeele, J Abrams, ES Alnemri, EH Baehrecke, MV Blagosklonny,WS El-Deiry, P Golstein, DR Green, M Hengartner, RA Knight, S Kumar, SA Lipton, W Malorni, G Nuñez, ME Peter, J Tschopp, J Yuan, M Piacentini, B Zhivotovsky, G Melino. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009; 16: 3-11.
  21. Li J, Karlsson MO, Brahmer J, Spitz A, et. al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst. 2006; 98: 1714-23.
  22. Lieberman JA, Jarskog LF, Glantz LA, et. al. Apoptotic mechanisms in the pathophysiology of schizophrenia. Department of Psychiatry, Schizophrenia Research Center, University of North Carolina-Chapel Hill, USA. 2005. Available from:
  23. Niidome T, Morimoto N, Iijima S, Akaike A , Kihara T , Sugimoto H. Mechanisms of cell death of neural progenitor cells caused y trophic support deprivation. Eur J Pharmacol. 2006; 548: 1-8.
  24. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol. 2005; 84: 627-39.
  25. Zamaraev AV, Kopeina GS, Prokhorova EA, et al. Post-translational Modification of Caspases: The Other Side of Apoptosis Regulation. Trends in cell biology. 2017. Available from: